Key result
Hypertrophic preconditioning with transient prohypertrophic stimulation significantly reduced the heart weight/body weight ratio compared to continuous stimulation at 6 weeks (5.32 vs 7.16 mg/g, P<0.01).
Why the study?
Does hypertrophic preconditioning attenuate cardiomyocyte hypertrophy and slow progression to heart failure in preclinical models?
Population
Mice and neonatal rat ventricular cardiomyocytes
Comparison
Hypertrophic preconditioning vs Continuous hypertrophic stimulation without…
Design
Preclinical
Follow-up
1 or 6 weeks
Authors
Loading...
May attenuate hypertrophy in animal models; leaves open clinical translation and human trials.
Does hypertrophic preconditioning attenuate cardiomyocyte hypertrophy and slow progression to heart failure in preclinical models?
Absolute Event Rate: 5.32% vs 7.16%
p-value: p=<0.01
Preconditioning with prohypertrophic factors exerts an antihypertrophic effect and slows the progression of heart failure in preclinical models, mediated by S100A8/A9 upregulation.
Wei et al. (2015) studied Myocardial hypertrophy and heart failure. Hypertrophic preconditioning vs. Continuous transverse aortic constriction (TAC) was evaluated on Heart weight/body weight (HW/BW) ratio at 6 weeks after TAC (p=<0.01). Hypertrophic preconditioning with transient prohypertrophic stimulation significantly reduced the heart weight/body weight ratio compared to continuous stimulation at 6 weeks (5.32 vs 7.16 mg/g, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: